Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanita', Roma, Italy.
MAbs. 2013 Jan-Feb;5(1):34-46. doi: 10.4161/mabs.22775. Epub 2012 Dec 4.
Monoclonal antibodies (mAb) have become a mainstay in tumor therapy. Clinical responses to mAb therapy, however, are far from optimal, with many patients presenting native or acquired resistance or suboptimal responses to a mAb therapy. MAbs exert antitumor activity through different mechanisms of action and we propose here a classification of these mechanisms. In many cases mAbs need to interact with immune cells to exert antitumor activity. We summarize evidence showing that interactions between mAbs and immune cells may be inadequate for optimal antitumor activity. This may be due to insufficient tumor accumulation of mAbs or immune cells, or to low-affinity interactions between these components. The possibilities to improve tumor accumulation of mAbs and immune cells, and to improve the affinity of the interactions between these components are reviewed. We also discuss future directions of research that might further improve the therapeutic efficacy of antitumor mAbs.
单克隆抗体 (mAb) 已成为肿瘤治疗的主要手段。然而，mAb 治疗的临床反应远非理想，许多患者对 mAb 治疗表现出天然或获得性耐药或反应不佳。mAbs 通过不同的作用机制发挥抗肿瘤活性，我们在这里提出了这些机制的分类。在许多情况下，mAbs 需要与免疫细胞相互作用才能发挥抗肿瘤活性。我们总结了表明 mAbs 与免疫细胞之间相互作用可能不足以产生最佳抗肿瘤活性的证据。这可能是由于 mAbs 或免疫细胞在肿瘤中的积累不足，或者这些成分之间的亲和力低。我们还讨论了可能进一步提高抗肿瘤 mAbs 治疗效果的未来研究方向。
